Literature DB >> 2471902

Differences in blood T and NK cell populations between chronic lymphocytic leukemia of B cell type (B-CLL) and monoclonal B-lymphocytosis of undetermined significance (B-MLUS).

E Kimby1, H Mellstedt, B Nilsson, M Björkholm, G Holm.   

Abstract

T and NK cell blood subpopulations were determined in 33 patients with B-CLL and in 14 patients with B-MLUS by two-color immunofluorescence. CLL patients had significantly higher total numbers of Leu-7+ and CD8+ cells and lower numbers of CD16+/Leu-7- cells as well as a higher Leu-7/CD16 ratio and a lower CD4/CD8 ratio than MLUS patients and control donors. Moreover, MLUS patients exhibited a significantly lower Leu-7/CD16 ratio as well as a higher frequency of CD16+/Leu-7- cells than healthy donors. These results suggest that B-CLL patients have higher numbers of circulating immature NK cells compared to B-MLUS, while B-MLUS patients have a larger proportion of NK cells with a high lytic capability as compared to both CLL and normal controls. The imbalance between CD4+ and CD8+ cells was prominent in CLL with a low CD4/CD8 ratio, but within the upper normal range in MLUS. Differences in immunoregulatory cell subpopulations between B-CLL and B-MLUS might therefore contribute to the different clinical behavior of these two disorders.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471902

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.

Authors:  Shahryar Kiaii; Aniruddha Choudhury; Fariba Mozaffari; Eva Kimby; Anders Osterborg; Håkan Mellstedt
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 2.  Growth and survival of B-chronic lymphocytic leukaemia cells.

Authors:  O Söderberg
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

3.  Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia.

Authors:  Régis T Costello; Benjamin Knoblauch; Carole Sanchez; Delphine Mercier; Thérèse Le Treut; Gérard Sébahoun
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

4.  Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia.

Authors:  Ola Landgren; Joshua S Rapkin; Neil E Caporaso; Lene Mellemkjaer; Gloria Gridley; Lynn R Goldin; Eric A Engels
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

Review 5.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.